AbbVie vs. AstraZeneca: Which Pharma Giant Has the Stronger Earnings Growth Story?

What happened: AbbVie (NYSE:ABBV) and AstraZeneca (NYSE:AZN) both reported earnings growth in their latest results, with AbbVie driven by immunology and AstraZeneca by oncology and rare disease. Key numbers: AbbVie Q2 2026 revenue rose 10.2% to $16.99 billion, adjusted EPS up 22.9% to $3.65. Why it matters: AbbVie shows stronger companywide revenue growth but concentration risk, since Skyrizi and Rinvoq contribute nearly half of quarterly revenue. AstraZeneca offers a broader therapeutic mix, though BioPharmaceuticals revenue fell 5% and weaker segments weigh on overall expansion.

AbbVie (NYSE:ABBV) and AstraZeneca (NYSE:AZN) both reported earnings growth in their latest results, with AbbVie driven by immunology and AstraZeneca by oncology and rare disease.

AbbVie shows stronger companywide revenue growth but concentration risk, since Skyrizi and Rinvoq contribute nearly half of quarterly revenue. AstraZeneca offers a broader therapeutic mix, though BioPharmaceuticals revenue fell 5% and weaker segments weigh on overall expansion.